• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy
In this study, dopamine-modified polyethylenimine (PEI) was prepared to fabricate an IR780 and siPD-L1 codelivery lipid-polymer hybrid nanoparticle (lip@PSD-siP) for the photothermal immunotherapy of CRC. The modification of dopamine can significantly reduce the cytotoxicity of PEI. lip@PSD-siP can be effectively taken up by CT26 cells and successfully escaped from lysosomes after entering the cells for 4 h. After CT26 cells were transfected with lip@PSD-siP, the PD-L1 positive cell rate decreased by 82.4%, and its PD-L1 knockdown effect was significantly stronger than the positive control Lipo3000-siP. In vivo studies sho...
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Di Chuan Rangrang Fan Bo Chen Yangmei Ren Min Mu Haifeng Chen Bingwen Zou Haohao Dong Aiping Tong Gang Guo Source Type: research

Core-shell tecto dendrimer-mediated cooperative chemoimmunotherapy of breast cancer
J Control Release. 2023 May 16:S0168-3659(23)00334-6. doi: 10.1016/j.jconrel.2023.05.021. Online ahead of print.ABSTRACTDevelopment of effective nanomedicines to deal with tumor immunogenicity and immunosuppression is vital to improve the immunotherapy efficacy. Herein, we developed a programmed strategy not only to activate the tumoral immune microenvironment through immunogenic cell death (ICD) effect but also to promote the maturation of dendritic cells (DCs) in lymph nodes through two modules of core-shell tecto dendrimer (CSTD)-based nanomedicines. The CSTDs with amplified tumor enhanced permeability and retention eff...
Source: Cancer Control - May 18, 2023 Category: Cancer & Oncology Authors: Cong Song Mengsi Zhan Zhijun Ouyang Yuge Yao Yue Gao Mingwu Shen Xiangyang Shi Source Type: research

IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth
CONCLUSION: In conclusion, IDO2-siRNA combined with nifuroxazide therapy could serve a significant role in the treatment of melanoma-bearing mice, enhance the tumor immunity and provide an experimental basis for identifying a novel combination method for the treatment of melanoma clinically.PMID:36999419 | DOI:10.2174/1874467217666230329102030
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Tiesuo Zhao Mengmeng Guo Haoqi Chen Lin Zhou Jing Guo Shenzhen Liu Zizhong Wang Wenshuai Huang Qiang Zhang Jiateng Zhong Mingyong Wang Huijie Jia Yongxi Zhang Source Type: research

Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Biomed Pharmacother. 2023 Mar 22;161:114567. doi: 10.1016/j.biopha.2023.114567. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal biomarkers for the prediction of response to this therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, termed zinc finger Asp-His-His-Cys-type palmitoyltransferases (ZDHHC), which precisely control vari...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Zhiqing Lin Keke Huang Hui Guo Manli Jia Qiuqin Sun Xuhao Chen Jianmin Wu Qingqing Yao Peng Zhang Sergii Vakal Zhengzhi Zou Haiyao Gao Lei Ci Jiangfan Chen Wei Guo Source Type: research

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
CONCLUSION: Our findings suggest a potential combination approach for cancer immunotherapy using PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs and PLGA (antigen+adjuvant)-NPs as novel immune checkpoint silencing agents.PMID:35228265 | DOI:10.1136/jitc-2021-003928
Source: Cancer Control - March 1, 2022 Category: Cancer & Oncology Authors: Ji Eun Won Youngseon Byeon Tae In Wi Chan Mi Lee Ju Hyeong Lee Tae Heung Kang Jeong-Won Lee YoungJoo Lee Yeong-Min Park Hee Dong Han Source Type: research

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
CONCLUSION: Our data suggest that the combination of decitabine with CAR T-cell therapy is an attractive novel therapeutic approach to enhance tumor-specific killing of bladder cancer. Since BID and BCL2L1 are essential determinants for the susceptibility of a wide variety of malignant cells, their targeting might be additionally suitable for combination with immunotherapies, e.g., CAR T-cells or checkpoint inhibitors in other malignancies.PMID:34868059 | PMC:PMC8637820 | DOI:10.3389/fimmu.2021.782448
Source: Cancer Control - December 6, 2021 Category: Cancer & Oncology Authors: Camilla M Grunewald Corinna Haist Carolin K önig Patrick Petzsch Arthur Bister Elfriede N ößner Constanze Wiek Kathrin Scheckenbach Karl K öhrer G ünter Niegisch Helmut Hanenberg Mich èle J Hoffmann Source Type: research